Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.93 CAD | -9.01% | -3.30% | +166.36% |
05-14 | Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure | MT |
04-22 | HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+166.36% | 161M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- CRDL Stock
- News Cardiol Therapeutics Inc.
- Cardiol Therapeutics Says Studies Show Cannabidiol-Based CardiolRx 'Significantly' Prevents Heart Dysfunction